Evidence map›Paper›PMID 28542712›Full record

SynthesisThe Cochrane database of systematic reviews2017

Histologic scoring indices for evaluation of disease activity in ulcerative colitis.

Mahmoud H Mosli, Claire E Parker, Sigrid A Nelson, Kenneth A Baker, John K MacDonald, G Y Zou, Brian G Feagan, Reena Khanna, Barrett G Levesque, Vipul Jairath

Abstract readSystematic Review
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review.The American journal of gastroenterology · 2019
    Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mahmoud H MosliKing Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia.
Claire E ParkerRobarts Clinical Trials, 100 Dundas Street, Suite 200, London, ON, Canada, N6A 5B6.
Sigrid A NelsonRobarts Clinical Trials, San Diego, CA, USA.
Kenneth A BakerRobarts Clinical Trials, 100 Dundas Street, Suite 200, London, ON, Canada, N6A 5B6.
John K MacDonaldCochrane IBD Group, Robarts Clinical Trials, 100 Dundas Street, Suite 200, London, ON, Canada, N6A 5B6.
G Y ZouRobarts Clinical Trials, 100 Dundas Street, Suite 200, London, ON, Canada, N6A 5B6.
Brian G FeaganRobarts Clinical Trials, 100 Dundas Street, Suite 200, London, ON, Canada, N6A 5B6.
Reena KhannaRobarts Clinical Trials, 100 Dundas Street, Suite 200, London, ON, Canada, N6A 5B6.
Barrett G LevesqueRobarts Clinical Trials, San Diego, CA, USA.
Vipul JairathRobarts Clinical Trials, 100 Dundas Street, Suite 200, London, ON, Canada, N6A 5B6.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDisease activity can be determined using clinical, endoscopic or histologic criteria in patients with ulcerative colitis (UC). Persistent disease activity is associated with poor outcomes. Histologic disease activity has been shown to be associated with relapse, colectomy and colorectal cancer. The ability to objectively evaluate microscopic disease activity using histology is important for both clinical practice and clinical trials. However, the operating properties of the currently available histologic indices remain unclear.

objectivesA systematic review was undertaken to identify and evaluate the development and operating characteristics of histologic disease activity indices used to assess disease activity in people with ulcerative colitis. SEARCH

methodsWe searched MEDLINE, EMBASE, PubMed, CENTRAL and the Cochrane IBD Review Group Specialized Trials Register from inception to 2 December 2016 for applicable studies. There were no language or document type restrictions. SELECTION CRITERIA: Any study design (e.g. randomized controlled trials, cohort studies, case series) that evaluated a histologic index in patients with UC were considered for inclusion. Eligible patients were adults (> 18 years), diagnosed with UC using conventional clinical, radiographic, endoscopic and histologic criteria. DATA COLLECTION AND ANALYSIS: Two authors (MHM and CEP) independently reviewed the titles and abstracts of the studies identified from the literature search. A standardized form was used to assess eligibility of trials for inclusion and for data extraction.Two authors (MHM and CEP) independently extracted and recorded data, which included the number of patients enrolled, number of patients per treatment arm, patient characteristics including age and gender distribution, and the name of the histologic index. Outcomes (i.e. intra-rater reliability, inter-rater reliability, internal consistency, content validity, criterion validity, construct validity, responsiveness, and feasibility) were recorded for each trial. MAIN

resultsIn total, 126 reports describing 30 scoring indices were identified through the screening process. Eleven of the 30 scoring indices have undergone some form of index validation. Intra-rater reliability was assessed for eight scoring indices. Inter-rater reliability was evaluated for all 11 of the scoring indices. Three of the indices underwent content validation. Two of the included scoring indices assessed criterion validity. Six of the included scoring indices explored content validity. Two of the included scoring indices were tested for responsiveness. AUTHORS'

conclusionsThe Nancy Index and the Robarts Histopathology Index have undergone the most validation in that four operating properties including reliability, content validity, construct validity (hypothesis testing) and criterion validity have been tested. However, none of the currently available histologic scoring indices have been fully validated. In order to determine the optimal endpoint for histologic healing in UC, more research is required. The optimal index would need to be fully validated.

Indexed as

Severity of Illness IndexBlood SedimentationColitis, UlcerativeC-Reactive ProteinFecesHumansLactoferrinLeukocyte CountLeukocyte L1 Antigen ComplexObserver VariationPancreatic ElastaseReproducibility of ResultsC-Reactive ProteinLactoferrinLeukocyte L1 Antigen ComplexPancreatic Elastase

Identifiers

PMID28542712
PMCPMC6481362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.